Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Common research-planning ranges (subcutaneous) Planning band Low Per-dose range ~250 mcg Frequency Once daily Typical context Maintenance / general research planning Planning band Standard Per-dose range ~250 mcg Frequency Twice daily Typical context Most published preclinical protocols and community references Planning band High Per-dose range ~500 mcg Frequency Twice daily Typical context Short-term acute-injury research planning These ranges reflect community-derived research planning
The math runs through RVUs
Among these antagonists free of edematogenic effects, [Ac-d-Nal(2)1, d-Phe(4Cl)2, d-Pal(3)3, d-Cit6, d-Ala10]LH-RH (SB-75), designated cetrorelix [Cetrotide], had high activity, and was synthesized first in our laboratory 20 and later also made by Zentaris 21
Our products are not intended to treat, prevent, mitigate or cure any disease or medical condition and are for research purposes only.
IM would require daily or every-other-day injections to achieve comparable cumulative fibroblast exposure
US$ 27.20
US$ 25.52
US$ 25.29
US$ 26.27
US$ 28.46
US$ 29.20
US$ 28.60
